Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Kufel

Physician Assistant Silver Spring, MD Physician Assistant

NPI 1437469723 CMS profile 11089004

8455 Colesville Rd, Suite 200, Silver Spring, MD 20910

Open in the dashboard

General payments

$12,545

679 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeffrey Kufel of Silver Spring, MD is reported in the CMS Open Payments database as having received $12,545 across 679 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,035 98
2024 General $2,074 110
2023 General $2,171 122
2022 General $2,817 158
2021 General $3,449 191

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Kufel
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Jeffrey Kufel were reported at $2,035. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Jeffrey Kufel Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $3,449 $132 $37–$438 $132
2022 $2,817 $155 $48–$522 $149
2023 $2,171 $167 $52–$557 $160
2024 $2,074 $178 $55–$600 $164
2025 $2,035 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $1,614 92 payments
  2. AbbVie, Inc. $1,242 84 payments
  3. AstraZeneca Pharmaceuticals LP $1,078 60 payments
  4. GlaxoSmithKline, LLC. $851 48 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $786 45 payments
  6. Amgen Inc. $779 48 payments
  7. Lilly USA, LLC $730 37 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $608 29 payments
  9. Sanofi-Aventis U.S. LLC $565 25 payments
  10. Janssen Pharmaceuticals, Inc $466 19 payments
  11. Other $3,826 192 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,545 679 payments
Products named General payments · program years 2021–2025
  1. Ozempic $1,329 77 payments
  2. RYBELSUS $1,253 73 payments
  3. TRELEGY ELLIPTA $769 43 payments
  4. Kerendia $608 29 payments
  5. GEMTESA $601 26 payments
  6. UBRELVY $574 40 payments
  7. Otezla $449 32 payments
  8. FARXIGA $441 26 payments
  9. XARELTO $424 17 payments
  10. MOUNJARO $394 21 payments
  11. Other $10,711 593 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

679 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record